Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Long-term Depression01:05

Long-term Depression

33.2K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
Long-term Depression01:03

Long-term Depression

3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.1K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

39.6K
Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
39.6K
Depressants01:28

Depressants

385
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
385
Depression: Overview01:18

Depression: Overview

813
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
813

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology·2026
Same author

Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesis.

Psychiatry research·2026
Same author

An Exploratory Study of Functional Outcome in Stimulant Treatment of ADHD in Adults.

Journal of attention disorders·2026
Same author

Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects.

PLOS mental health·2026
Same author

Are the current safety measures for the treatment of depression with esketamine sufficient?

Expert opinion on drug safety·2026
Same author

Effects of Adjunctive Brexpiprazole in Major Depressive Disorder Analyzed by Baseline Anxiety Level: Post Hoc Analysis of a Phase 4 Study.

Journal of clinical psychopharmacology·2025

Related Experiment Video

Updated: Jan 22, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K

Esketamine for treatment resistant depression.

Jennifer Swainson1,2, Rejish K Thomas1,3, Shaina Archer1

  • 1Department of Psychiatry, University of Alberta , Edmonton , AB , Canada.

Expert Review of Neurotherapeutics
|July 9, 2019
PubMed
Summary

Esketamine offers a novel treatment for Treatment Resistant Depression (TRD) when standard antidepressants fail. This review covers its pharmacology, clinical data, and expert opinions on its use.

Keywords:
Esketamineglutamateketaminenmda receptortreatment resistant depression

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.5K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K

Related Experiment Videos

Last Updated: Jan 22, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.5K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Treatment Resistant Depression (TRD) presents a significant clinical challenge with limited therapeutic options.
  • Esketamine, the S-enantiomer of ketamine, has received FDA approval for TRD.
  • Current treatment paradigms for TRD are often insufficient, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To review current treatment options for TRD.
  • To provide a comprehensive overview of esketamine, including its pharmacology, clinical efficacy, and safety.
  • To discuss expert opinions on the integration of esketamine into TRD treatment protocols.

Main Methods:

  • Literature search of relevant databases to identify studies on TRD and esketamine.
  • Review of clinical trial data (Phase 2-3) for esketamine's efficacy and safety.
  • Inclusion of expert opinions on factors influencing esketamine's clinical utility.

Main Results:

  • Esketamine demonstrates potential as a novel treatment for TRD.
  • Clinical trial data indicate efficacy and safety profiles for esketamine.
  • Expert opinion highlights patient, physician, and social factors impacting esketamine use.

Conclusions:

  • Esketamine represents a significant advancement in managing Treatment Resistant Depression.
  • While questions regarding optimal dosing and long-term risks persist, esketamine offers new hope.
  • Its FDA approval and emerging safety data position it as a promising alternative to off-label ketamine use.